Total Payments
$191,760
2024 Payments
$79,802
Companies
27
Transactions
214
Medicare Patients
517
Medicare Billing
$169,858
Payment Breakdown by Category
Other$132,014 (68.8%)
Consulting$28,084 (14.6%)
Travel$24,666 (12.9%)
Food & Beverage$6,164 (3.2%)
Education$833.47 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $128,819 | 30 | 67.2% |
| Consulting Fee | $28,084 | 10 | 14.6% |
| Travel and Lodging | $24,666 | 71 | 12.9% |
| Food and Beverage | $6,164 | 92 | 3.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,195 | 2 | 1.7% |
| Education | $833.47 | 9 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $83,169 | 63 | $0 (2024) |
| Kite Pharma, Inc. | $66,372 | 66 | $0 (2023) |
| Incyte Corporation | $18,783 | 33 | $0 (2024) |
| CTI BioPharma Corp. | $10,195 | 2 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $4,152 | 2 | $0 (2024) |
| Medexus Pharma, Inc. | $2,381 | 4 | $0 (2024) |
| Gamida Cell Inc. | $2,191 | 5 | $0 (2024) |
| Celgene Corporation | $843.99 | 6 | $0 (2024) |
| McKesson Drug Company LLC | $610.00 | 1 | $0 (2023) |
| ZOLL Medical Corporation | $520.00 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $79,802 | 80 | SANOFI-AVENTIS U.S. LLC ($56,103) |
| 2023 | $84,511 | 71 | Kite Pharma, Inc. ($41,466) |
| 2022 | $18,675 | 38 | Kite Pharma, Inc. ($17,734) |
| 2021 | $5,231 | 7 | Kite Pharma, Inc. ($4,957) |
| 2020 | $2,215 | 3 | Kite Pharma, Inc. ($2,215) |
| 2019 | $164.99 | 2 | Amgen Inc. ($164.99) |
| 2018 | $853.26 | 9 | Amgen Inc. ($315.09) |
| 2017 | $307.93 | 4 | Millennium Pharmaceuticals, Inc. ($193.46) |
All Payment Transactions
214 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Incyte Corporation | NIKTIMVO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $685.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $127.33 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $39.36 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,822.50 | General |
| Category: Hematology/Oncology | ||||||
| 11/21/2024 | ZOLL Medical Corporation | Defibrillator (Device) | Consulting Fee | Cash or cash equivalent | $520.00 | General |
| Category: Resuscitation | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,238.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | In-kind items and services | $701.27 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $261.11 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $161.48 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | Cash or cash equivalent | $141.19 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $117.49 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $12.21 | General |
| Category: Oncology | ||||||
| 11/19/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $8.05 | General |
| Category: Oncology | ||||||
| 11/18/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,307.00 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $797.96 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $233.90 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $132.40 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $87.93 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $36.21 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $34.60 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.35 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.05 | General |
| Category: Hematology/Oncology | ||||||
| 11/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $8.50 | General |
| Category: Hematology/Oncology | ||||||
| 11/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $46.04 | General |
| Category: Hematology/Oncology | ||||||
| 11/07/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.99 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 163 | 996 | $148,469 | $46,669 |
| 2022 | 5 | 109 | 504 | $116,209 | $41,638 |
| 2021 | 6 | 144 | 641 | $140,331 | $49,533 |
| 2020 | 4 | 101 | 370 | $86,719 | $32,018 |
Total Patients
517
Total Services
2,511
Medicare Billing
$169,858
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 152 | $34,976 | $14,066 | 40.2% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 30 | 497 | $44,283 | $11,728 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 28 | 100 | $31,970 | $10,734 | 33.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 32 | 202 | $20,063 | $4,734 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $7,173 | $2,119 | 29.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $6,719 | $2,037 | 30.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 13 | 14 | $3,285 | $1,252 | 38.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 185 | $40,230 | $14,705 | 36.6% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 30 | 164 | $38,295 | $14,080 | 36.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 86 | $26,010 | $9,487 | 36.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 13 | $5,500 | $1,998 | 36.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 18 | 56 | $6,173 | $1,368 | 22.2% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 37 | 213 | $49,099 | $18,229 | 37.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 183 | $39,160 | $14,326 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 93 | $27,212 | $9,980 | 36.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 20 | $8,342 | $3,101 | 37.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 24 | 120 | $13,823 | $2,983 | 21.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 12 | $2,696 | $913.98 | 33.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 188 | $40,230 | $15,067 | 37.5% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 30 | 99 | $22,820 | $8,920 | 39.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 40 | $11,704 | $3,438 | 29.4% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 14 | 32 | $7,376 | $2,879 | 39.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 11 | 11 | $4,588 | $1,714 | 37.3% |
About Dr. Sagar Patel, M.D
Dr. Sagar Patel, M.D is a Internal Medicine healthcare provider based in Edina, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2012. The National Provider Identifier (NPI) number assigned to this provider is 1528327210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sagar Patel, M.D has received a total of $191,760 in payments from pharmaceutical and medical device companies, with $79,802 received in 2024. These payments were reported across 214 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($128,819).
As a Medicare-enrolled provider, Patel has provided services to 517 Medicare beneficiaries, totaling 2,511 services with total Medicare billing of $169,858. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Edina, MN
- Active Since 05/15/2012
- Last Updated 11/11/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1528327210
Products in Payments
- REZUROCK (Drug) $83,169
- Yescarta (Drug) $18,862
- JAKAFI (Drug) $18,038
- Vonjo (Drug) $10,195
- OMISIRGE (Biological) $2,191
- NIKTIMVO (Drug) $685.00
- Defibrillator (Device) $520.00
- VENCLEXTA (Drug) $280.93
- clonoSEQ (Device) $205.39
- VELCADE (Drug) $197.48
- RUCONEST (Biological) $138.64
- DEFITELIO (Drug) $137.25
- ONUREG (Drug) $134.79
- Rezurock (Drug) $133.48
- XGEVA (Biological) $121.09
- RYLAZE (Drug) $99.55
- ADCETRIS (Biological) $93.00
- XPOVIO (Drug) $87.35
- IMBRUVICA (Drug) $85.00
- NINLARO (Drug) $82.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Edina
Dr. Merlin Brown, Md, MD
Internal Medicine — Payments: $16,895
Internal Medicine $16,895
Rupesh Ranjan, M.d, M.D
Internal Medicine — Payments: $3,629
Internal Medicine $3,629
Christopher Stefonowicz, Md, MD
Internal Medicine — Payments: $2,876
Internal Medicine $2,876
Joshua Waytz, Md, MD
Internal Medicine — Payments: $1,914
Internal Medicine $1,914
Michael Cummings, Md, MD
Internal Medicine — Payments: $723.54
Internal Medicine $723.54
Ahmad Raza, Md, MD
Internal Medicine — Payments: $456.44
Internal Medicine $456.44